BidaskClub upgraded shares of Stemline Therapeutics (NASDAQ:STML) from a hold rating to a buy rating in a research note published on Thursday.
STML has been the topic of a number of other reports. ValuEngine raised Stemline Therapeutics from a sell rating to a hold rating in a research note on Sunday, December 31st. HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the stock a buy rating in a research note on Thursday, December 14th. Finally, Cowen reaffirmed a buy rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Stemline Therapeutics presently has a consensus rating of Buy and an average target price of $33.75.
Stemline Therapeutics (STML) traded down $0.80 during trading on Thursday, hitting $15.20. The company had a trading volume of 223,500 shares, compared to its average volume of 256,400. The firm has a market capitalization of $370.45, a price-to-earnings ratio of -5.91 and a beta of -0.02. Stemline Therapeutics has a one year low of $5.50 and a one year high of $16.20.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $14.18, for a total value of $169,351.74. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 16.70% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Empire Life Investments Inc. acquired a new position in Stemline Therapeutics in the third quarter valued at approximately $373,000. Cowen Inc. acquired a new position in Stemline Therapeutics in the third quarter valued at approximately $420,000. Lyon Street Capital LLC lifted its stake in Stemline Therapeutics by 331.1% in the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after buying an additional 415,867 shares during the period. Dimensional Fund Advisors LP lifted its stake in Stemline Therapeutics by 82.0% in the third quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock valued at $2,434,000 after buying an additional 98,775 shares during the period. Finally, C WorldWide Group Holding A S acquired a new position in Stemline Therapeutics in the third quarter valued at approximately $1,776,000. 50.24% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Stemline Therapeutics (STML) Upgraded to “Buy” by BidaskClub” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2018/01/05/stemline-therapeutics-stml-upgraded-to-buy-by-bidaskclub.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.